Hillevax Inc

NASDAQ HLVX

Data sourced from

and

Download Data

Hillevax Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 190.47%

Hillevax Inc Selling, General, and Administrative Expenses (SG&A) 3 year CAGR is 190.47% for the Trailing 12 Months (TTM) ending March 31, 2024. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Hillevax Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 19.90 M, a 177.85% change year over year.
Hillevax Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 7.16 M, a 497.75% change year over year.
Hillevax Inc Selling, General, and Administrative Expenses (SG&A) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.20 M.

NASDAQ: HLVX

Hillevax Inc

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street, Boston, MA, United States, 02109
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Key trends